Search research articles
Contact Us
Filters
Showing results (611-620 of 675) with videos related to
Page
of 68
Sort By:
Cancer
|
May 22, 2014
Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments
Laura D Locati, Lisa Licitra, Laura Agate, et al.
The Laryngoscope
|
January 24, 2024
Recovery of Recurrent Laryngeal Nerve Function With Neoadjuvant Treatment: Neural Characterization
Marika D Russell, Amr H Abdelhamid Ahmed, Zipei Feng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 1, 2009
Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer
Martin J Schlumberger, Rossella Elisei, Lars Bastholt, et al.
Medrxiv : the Preprint Server for Health Sciences
|
February 20, 2025
Personalized circulating tumor DNA dynamics predict survival and response to immune checkpoint blockade in recurrent/metastatic head and neck cancer
Daniel A Ruiz-Torres, Ross D Merkin, Michael Bryan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 26, 2024
Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers
Jena D French, Bryan R Haugen, Francis P Worden, et al.
Cancer Medicine
|
March 24, 2016
Outcome of patients with nonmetastatic muscle-invasive bladder cancer not undergoing cystectomy after treatment with noncisplatin-based chemotherapy and/or radiotherapy: a retrospective analysis
Aristotle Bamias, Petros Tsantoulis, Thomas Zilli, et al.
Oral Oncology
|
June 6, 2021
A phase II trial of all-trans retinoic acid (ATRA) in advanced adenoid cystic carcinoma
Glenn J Hanna, Anne ONeill, Jennifer M Cutler, et al.
Thyroid : Official Journal of the American Thyroid Association
|
June 6, 2022
Dabrafenib Versus Dabrafenib + Trametinib in <i>BRAF</i>-Mutated Radioactive Iodine Refractory Differentiated Thyroid Cancer: Results of a Randomized, Phase 2, Open-Label Multicenter Trial
Naifa L Busaidy, Bhavana Konda, Lai Wei, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 2, 2024
Durability of Response With Selpercatinib in Patients With <i>RET</i>-Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001
Lori J Wirth, Marcia S Brose, Vivek Subbiah, et al.
The Lancet. Oncology
|
July 13, 2026
Efficacy and safety of dabrafenib plus trametinib in adults with differentiated thyroid cancer: a randomised, double-blind, placebo-controlled, phase 3 trial
Ming Gao, Young Joo Park, Chia-Chi Lin, et al.
Page
of 68
Search research articles
Search
Showing results (611-620 of 675) with videos related to
Sort By:
Page
of 68
Cancer
|
May 22, 2014
Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments
Laura D Locati, Lisa Licitra, Laura Agate, et al.
The Laryngoscope
|
January 24, 2024
Recovery of Recurrent Laryngeal Nerve Function With Neoadjuvant Treatment: Neural Characterization
Marika D Russell, Amr H Abdelhamid Ahmed, Zipei Feng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 1, 2009
Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer
Martin J Schlumberger, Rossella Elisei, Lars Bastholt, et al.
Medrxiv : the Preprint Server for Health Sciences
|
February 20, 2025
Personalized circulating tumor DNA dynamics predict survival and response to immune checkpoint blockade in recurrent/metastatic head and neck cancer
Daniel A Ruiz-Torres, Ross D Merkin, Michael Bryan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 26, 2024
Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers
Jena D French, Bryan R Haugen, Francis P Worden, et al.
Cancer Medicine
|
March 24, 2016
Outcome of patients with nonmetastatic muscle-invasive bladder cancer not undergoing cystectomy after treatment with noncisplatin-based chemotherapy and/or radiotherapy: a retrospective analysis
Aristotle Bamias, Petros Tsantoulis, Thomas Zilli, et al.
Oral Oncology
|
June 6, 2021
A phase II trial of all-trans retinoic acid (ATRA) in advanced adenoid cystic carcinoma
Glenn J Hanna, Anne ONeill, Jennifer M Cutler, et al.
Thyroid : Official Journal of the American Thyroid Association
|
June 6, 2022
Dabrafenib Versus Dabrafenib + Trametinib in <i>BRAF</i>-Mutated Radioactive Iodine Refractory Differentiated Thyroid Cancer: Results of a Randomized, Phase 2, Open-Label Multicenter Trial
Naifa L Busaidy, Bhavana Konda, Lai Wei, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 2, 2024
Durability of Response With Selpercatinib in Patients With <i>RET</i>-Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001
Lori J Wirth, Marcia S Brose, Vivek Subbiah, et al.
The Lancet. Oncology
|
July 13, 2026
Efficacy and safety of dabrafenib plus trametinib in adults with differentiated thyroid cancer: a randomised, double-blind, placebo-controlled, phase 3 trial
Ming Gao, Young Joo Park, Chia-Chi Lin, et al.
Page
of 68